Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 30Recruiting 11Terminated 5Unknown 3Active not recruiting 3Suspended 1Not yet recruiting 1Available 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Brain Neoplasms 152Glioblastoma 147Glioma 94Neuroblastoma 50Medulloblastoma 33Central Nervous System Neoplasms 27Astrocytoma 27Neoplasms 24Ependymoma 23Sarcoma 22Carcinoma, Non-Small-Cell Lung 22Neurofibromatosis 1 20Melanoma 20Breast Neoplasms 20Rhabdomyosarcoma 18Osteosarcoma 18Sarcoma, Ewing 16Lung Neoplasms 16Gliosarcoma 16Rhabdoid Tumor 15Oligodendroglioma 15Wilms Tumor 13Meningioma 13Hepatoblastoma 13Diffuse Intrinsic Pontine Glioma 13Recurrence 12Neurofibroma, Plexiform 11Neoplasm Metastasis 11Meningeal Carcinomatosis 11Lymphoma, Non-Hodgkin 11

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neurofibromatoses × CNS × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03873610 2025-12-26

Resiliency Training in Adolescents With NF1 and NF2

Massachusetts General Hospital

Phase NA Active not recruiting
200 enrolled
CNS

Neurofibromatoses

NCT05581511 2025-10-14

cNF Natural Hx

Johns Hopkins University

Active not recruiting
500 enrolled
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡